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Abstract
Regional lymphnodemetastasis is a critical event in oral
tongue squamous cell carcinoma (OTSCC) progression.
The identification of biomarkers associated with the
metastatic process would provide critical prognostic
information to facilitate clinical decision making for
improved management of OTSCC patients. Global
expressional profiles were obtained for 25 primary
OTSCCs, where 11 cases showed lymph node metas-
tasis (pN+) histologically and 14 cases were non-
metastatic (pN). Seven of pN+ cases also exhibited
extracapsular spread (ECS)ofmetastaticnodes.Multiple
expression indices were used to generate signature
gene sets for pN+/ and ECS+/ cases. Selected genes
from signature gene sets were validated using quantita-
tive reverse transcription–polymerase chain reaction
(qRT-PCR). The classification powers of these genes
were then evaluated using a logistic model, receiver
operating characteristic curve analysis, and leave-one-
out cross-validation. qRT-PCR validation data showed
that differences at RNA levels are either statistically
significant (P < .05) or suggestive (P < .1) for six of eight
genes tested (BMP2, CTTN, EEF1A1,GTSE1,MMP9, and
EGFR) for pN+/ cases, and for five of eight genes tested
(BMP2, CTTN, EEF1A1, MMP9, and EGFR) for ECS+/
cases. Logistic models with specific combinations of
genes (CTTN+MMP9+EGFR for pN and CTTN+EEF1A1+
MMP9 for ECS) achieved perfect specificity and sensi-
tivity. Leave-one-out cross-validation showed overall
accuracy rates of 85% for both pN and ECS prediction
models. Our results demonstrated that the pN and the
ECS of OTSCCs can be predicted by gene expression
analyses of primary tumors.
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Introduction
Head and neck squamous cell carcinomas (HNSCCs) are a
heterogeneous group of tumors that arise from the epithelium
of the upper aerodigestive tract. HNSCC is the sixth most
common malignancy in humans and is associated with high
alcohol and tobacco use. Despite tremendous improvements
in surgery, radiotherapy, and chemotherapy over the last de-
cade, the prognosis for patients with HNSCC has been more or
less unchanged for the past three decades. This is because
patients continue to die from metastatic diseases at regional
and distant sites. Improvement in patient survival requires an
increased understanding of tumor metastasis so that aggres-
sive tumors can be detected early in the disease process and
targeted therapeutic interventions can be developed. Detection
of local lymph node metastasis is pivotal for choosing appropri-
ate treatment, especially for individuals diagnosed with HNSCC
in the oral cavity or oropharynx [1]. Most of these individuals
have their primary tumor removed. Treatment of individuals
clinically diagnosed with lymph node metastasis (pN+ status)
involves additional surgical removal of a substantial portion of
the neck, including all five local lymph node levels [called radical
neck dissection (RND)]. On histologic examination of removed
tissues, 10% to 20% of clinically diagnosed pN+ individuals turn
out to be metastasis-free (pN) [2]. Clinical diagnosis of pN
status is even less accurate. Postoperative histologic examina-
tion shows that approximately one third of clinically diagnosed
pN individuals have metastasis-positive lymph nodes in the
neck [3]. Currently, there are several different strategies for
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treating diagnosed pN individuals [4]. In the ‘‘watch-and-
wait’’ strategy, diagnosed pN individuals do not undergo any
neck dissection; this risks fatality by allowing overlooked
metastases to spread further. Because false-negative rate
is very high, most clinics carry out neck surgery for all
diagnosed pN individuals. In these cases, supraomohyoid
neck dissection (SOHND) is performed, which removes the
three upper lymph node levels [5]. SOHND is less appropriate
than RND for pN+ individuals falsely diagnosed as pN and,
moreover, is completely unnecessary for individuals correctly
diagnosed as pN. Although SOHND is less rigorous than
RND, the treatment causes disfigurement, long-term discom-
fort, and pain, and can lead to additional complications such
as shoulder and neck disability [6–9]. Both strategies result in
inappropriate treatment because of limitations in reliably
detecting lymph node metastasis. In addition to nodal me-
tastasis, many studies have also suggested that extracap-
sular spread (ECS) of lymph node metastasis is one of the
most important negative prognostic factors for several differ-
ent cancer types [10–13], including head and neck cancers
[14,15]. The detection of ECS is currently performed by
histologic examination of dissected lymph nodes, which is
also prone to the same limitations as for current methods of
nodal metastasis diagnosis. This points to an immediate
need for new diagnostic strategies.
Currently, no molecular biomarkers have been included in
clinical work-up strategies for the detection of nodal metas-
tasis and ECS. Because several genes have been reported in
retrospective trials to yield prognostic information indepen-
dently of Tumor–Node–Metastasis (TNM) classification, it is
reasonable to hypothesize that molecular ‘‘fingerprints’’ that
might define subgroups of patients with significantly more
aggressive disease could exist. Tumor cells may progress via
the bloodstream or the lymphatic system to colonize new
areas of the body. Gene expression signatures of primary
tumors have been identified in several tumor types for an
increased risk of metastasis [16,17]. The metastasis of
HNSCCs is unique in that theymetastasizemainly to regional
lymph nodes through the draining lymphatics, where metas-
tasis to distant sites is relatively uncommon. Several recent
gene expression studies have suggested the existence of
such fingerprints in primary tumors for the metastasis of
HNSCC [18–20]. In this study, we carry out a genomewide
expression analysis of oral tongue squamous cell carcinoma
(OTSCC) to identify these fingerprints for nodalmetastasis as
well as for ECS, and to further validate them using quantita-
tive reverse transcription–polymerase chain reaction (qRT-
PCR). Transcriptional profiling capable of predicting ECS
phenotypes has not been reported previously; thus, our study
should have high substantive significance.
Materials and Methods
Tumor Procurement and RNA Extraction
Discarded surgically resected tissues from T4 OTSCC
patients were obtained for this study. This study has been
approved by the Institutional Review Boards at the University
of California at Los Angeles and the Institut Gustave-Roussy.
These tissues were snap-frozen. Clinical characterizations
of these patients are outlined in Table 1. There are no signifi-
cant statistical differences in age and gender among all
patient groups (P > .1). Tumor stage was determined accord-
ing to the designated classification of the American Joint
Committee on Cancer.
Cancer tissues containing > 80% tumor cells, based on
hematoxylin–eosin staining and pathological examination,
were identified and selectively microdissected by a trained
pathologist. Total RNA was isolated using RNeasy Mini kit
(Qiagen, Valencia, CA) and was quantified by the RiboGreen
RNAQuantitation Reagent (Molecular Probes, Carlsbad, CA).
Array Hybridization and Data Analysis
Fifty to 200 ng of purified total RNA was amplified by a
modified T7 RNA amplification protocol, as described pre-
viously [21]. The Enzo BioArray High Yield RNA Transcript
Labeling System (Enzo, Farmingdale, NY) was used for
labeling the sample before hybridization. Biotinylated cRNA
(IVT product) was purified using theRNeasy kit (Qiagen). The
quantity and the purity of biotinylated cRNA were determined
by spectrophotometry, and an aliquot of the sample was
checked by gel electrophoresis. The sample was hybridized
to the Affymetrix Human Genome U133 Plus 2.0 GeneChip
arrays (Affymetrix, Santa Clara, CA) according to Affymetrix
protocols. The arrays were scanned with a GeneChip Scan-
ner 3000. The scanned array images were processed with
GeneChip Operating software (GCOS). Microarray data
were analyzed using three common microarray analysis
methods, including the Affymetrix Microarray Analysis Suite
version 5.0 (MAS 5.0) (which is now implemented in GCOS)
[22], the Model Based Expression Index (MBEI) from Li and
Wong [23] (implemented in dChip), and Robust Multiarray
Analysis (RMA) from Irizarry et al. [24]. Three separate
candidate gene lists of similar sizes (f100 top genes) were
generated by stringent statistical criteria of t-test statistics
and by fold change for both pN and ECS groupings (99 and
103 transcripts were selected using dChip with P < .0033 and
Table 1. Clinical Characterization of OTSCC Patients.
pN (n = 14) pN+, ALL (n = 11) pN+, ECS+ (n = 7)
Age (years)
Median 54 65 66
Range 41–67 37–82 37–78
Mean 55 61 63
Gender (%)
Male 86 64 43
Female 14 36 57
Tumor site (%)
Tongue 100 100 100
Pathological T stage (%)
Stage 4 100 100 100
Pathological N stage (%)
Stage 0 100 0 0
Stage 1 0 9 0
Stage 2 0 91 100
Pathological M stage (%)
Stage 0 93 100 100
Stage 1 7 0 0
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P < .00095 and > 1.9-fold and 2.02-fold change in intensity for
pN and ECS, respectively; 99 and 98 transcripts were selected
using MAS 5.0 with P < .018 and P < .015 and > 2.42-fold
and 2.45-fold change in intensity for pN and ECS, respec-
tively; 102 and 99 transcripts were selected using RMA with
P < .002 and P < .002 and > 1.17-fold and 1.16-fold change
in log intensity for pN and ECS, respectively). To narrow down
candidate genes, a signature gene list was compiled by se-
lecting genes present in at least two of three initial candidate
gene lists. The rationale is that using a combination of sev-
eral methods increases statistical power to detect a true
biomarker, reduces chances of false-positives, and improves
reproducibility in future validation experiments.
To display the consistency of the expression pattern of
signature gene sets, we performed average linkage hierar-
chical clustering, an unsupervised method, and multidimen-
sional scaling (MDS). The goal of hierarchical clustering is
to graphically display the similarity between genes and
samples. MDS is a visualization method used to project
differences in gene expression patterns among samples
into a multidimensional space and to reveal underlying struc-
tures that explain observed similarities among samples.
qRT-PCR
Based on their statistical significance and biologic rele-
vance, selected candidate genes from the signature gene
list were chosen for further validation using qRT-PCR. qRT-
PCR was performed on all 25 cases of OTSCC, as described
previously [25]. RNA was converted to first-strand cDNA
using MuLV reverse transcriptase (Applied Biosystems,
Foster City, CA), and qPCR was performed using iQ SYBR
Green Supermix (Bio-Rad, Hercules, CA) in a Bio-Rad
iCycler iQ real-time PCR detection system. All reactions were
performed in triplicate. Melting curve analyses were per-
formed to ensure the specificity of qRT-PCR. Primer sets
used to test the expression of these selected candidate
genes are listed in Table 2. Data analysis was performed
using the 2DDCt method described previously [26], where
b-actin was used as reference gene. qRT-PCR–based gene
expression values between two groups were compared by
nonparametric Wilcoxon test.
Prediction Models
To evaluate the classification power for each gene, re-
ceiver operating characteristic (ROC) curve analysis is per-
formed based on a logistic model with a binary outcome of
pN+/ (or ECS+/) as a dependent variable and with the qRT-
PCR value of a candidate gene as an independent variable.
The ROC curve shows sensitivity on the y axis and (1 
specificity) on the x axis for each possible cut point of fitted
probabilities from themodel. The area under the curve (AUC)
was computed through numerical integration of the ROC
curve, which measures the overall diagnostic/classification
power. In addition, the set of sensitivity and specificity is
shown using the best cut point value suggested, which
minimizes the absolute value of sensitivity minus specificity.
Multivariate classification models were also constructed to
determine the best combination of selected candidate genes
for pN+/ (or ECS+/). Using the binary outcomes of pN+/ (or
ECS+/) as dependent variables, the best-fit logistic model
was constructed by stepwise model selection method for
pN+/ (or ECS+/) groupings [27]. ROC analysis was per-
formed on this model. We also used leave-one-out cross-
validation to evaluate the logistic regression model, as
described previously [28]. In brief, this validation procedure
removes one observation and finds the best logistic model
using stepwise selection with the remaining cases. Then,
we predict the class of the left-out case in the best logistic
model. This procedure is repeated for each of the observa-
tions. The cross-validated accuracy rate is the percentage of
all models that correctly predict the left-out sample.
Results
Global gene expression profiling was performed using Affy-
metrixGeneChipU133+2.0 array on 11 lymph nodemetastatic
(pN+) and 14 nonmetastatic negative (pN) OTSCC samples.
A signature gene set for pN+ and pN cases (33 genes;
Table 3) was generated by integrating three microarray analy-
ses (MAS 5.0, dChip, and RMA), as described in the Materials
and Methods section. This signature gene set provides the
classification value for the pN+ and pN groups (Figure 1). The
hierarchical clustering misclassified one for each of two
groups (Figure 1A). Apparent separation between pN+ and
pN groups was observed on MDS (Figure 1B).
In our pN+ patient cohort, seven had been clinically diag-
nosed as ECS+. A second signature gene list for ECS+/
(22 genes; Table 3) was generated by integrating three micro-
array analysis methods (MAS 5.0, dChip, and RMA), as
described in the Materials and Methods section. This sig-
nature gene set can provide superb classification power for
Table 2. Primer Used for Real-Time qRT-PCR.
Gene Symbol Gene Name Affymetrix Probe ID Forward Primer Reverse Primer
BMP2 Bone morphogenetic protein 2 205289_AT aactctcctcctgcccctta tgcaggttcatcgttttcct
EEF1A1 Eukaryotic translation elongation factor 1 a1 204892_X_AT agtctggtgatgctgccatt gcgacccaaaggtggatagt
CTTN Cortactin 214782_AT ctgagttcttccttccccact taaatgtgcaggccaaacaag
GTSE1 G-2 and S-phase expressed 1 204318_S_AT gttctaagccgaaccaaatcc acctcagcctcccaagttcta
ASAH1 N-acylsphingosine amidohydrolase (acid ceramidase) 1 213902_AT ttgcctcttcgtgaactttg accacccaaataccctgttg
MMP9 Matrix metalloproteinase 9 203936_S_AT gcacgacgtcttccagtacc tcaactcactccgggaactc
EGFR Epidermal growth factor receptor 201983_S_AT gcatctttaagggctccaca actatcctccgtggtcatgc
MTUS1 Mitochondrial tumor suppressor 1 212096_S_AT tatctctgctcacgcttcca cagcagggaacaacacaaga
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ECS+/ (Figure 2). The hierarchical clustering misclassified
one for each of two groups (Figure 2A). Apparent separa-
tion between ECS+ and ECS groups was observed on
MDS (Figure 2B).
qRT-PCR was performed to validate the expressional
differences of eight candidate genes in the cases we used
for global expression profiling study. As shown in Table 4,
differences in RNA levels are either statistically significant
(P < .05) or suggestive (P < .1) for six of eight genes tested
for pN versus pN+ (including BMP2, CTTN, EEF1A1,
GTSE1,MMP9, andEGFR). For the ECS andECS+ groups,
five of eight genes tested show either statistically significant
(P < .05) or suggestive (P < .1) differences in RNA levels
(including BMP2, CTTN, EEF1A1, MMP9, and EGFR).
To test the prediction/classification power of these
markers, a logistic model and ROC curve analysis were
performed based on qRT-PCR results (Table 5). CTTN
and MMP9 show the best prediction powers (0.94 and
0.88 AUC, respectively, for pN; 0.88 and 0.95 AUC, respec-
tively, for ECS). Specific combinations of markers (CTTN+
MMP9+EGFR for pN+/;CTTN+EEF1A1+MMP9 for ECS+/)
that fit the data best achieved perfect specificity and sensi-
tivity. As evaluated by leave-one-out cross-validation, 85%
overall prediction accuracy rates were achieved for both
specific marker combinations for pN+/ and ECS+/. Our
results demonstrated that pN metastasis and ECS can be
predicted by gene expression analyses. This provides a foun-
dation for further validation of the prediction/classification
Table 3. Signature Gene Sets for pN Metastasis and ECS Based on the Intersection of Three Different Expression Indices.
Signature Gene Set for pN+/ Signature Gene Set for ECS+/
Probe ID Gene Title Gene
Symbol
Intersect* Probe ID Gene Title Gene
Symbol
Intersect*
Genes upregulated in pN+ cases Genes upregulated in ECS+ cases
226368_at Carbohydrate sulfotransferase 11 CHST11 2 205100_at Glutamine-fructose-6-phosphate
transaminase 2
GFPT2 2
214782_at Cortactin CTTN 3 204318_s_at G-2 and S-phase expressed 1 GTSE1 3
204318_s_at G-2 and S-phase expressed 1 GTSE1 2 236524_at b-Amyloid binding protein precursor BBP 2
214375_at PTPRF-interacting protein,
binding protein 1
PPFIBP1 2 205290_s_at Bone morphogenetic protein 2 BMP2 2
218414_s_at Nude, A. nidulans, homolog of, 1 NDE1 2 226368_at Carbohydrate sulfotransferase 11 CHST11 2
219557_s_at Nuclear receptor interacting protein 3 NRIP3 2 214782_at Cortactin CTTN 2
223940_x_at Metastasis-associated lung
adenocarcinoma transcript 1
MALAT1 2 229579_s_at Dispatched homolog 2 DISP2 3
210235_s_at Protein tyrosine phosphatase,
receptor type, of polypeptide,
interacting protein, a1
PPFIA1 3 232120_at Epidermal growth factor receptor EGFR 2
242509_at MGC17624 protein MGC17624 2 203936_s_at Matrix metalloproteinase 9 MMP9 2
1553185_at RAS and EF hand domain containing RASEF 3 219557_s_at Nuclear receptor interacting
protein 3
NRIP3 2
236947_at Semaphorin 3C SEMA3C 3 1559400_s_at Pregnancy-associated plasma
protein A, pappalysin 1
PAPPA 3
215715_at Solute carrier family 6, member 2 SLC6A2 2 213577_at Squalene epoxidase SQLE 2
243834_at Trinucleotide repeat containing 6A TNRC6A 3 243834_at Trinucleotide repeat containing 6A TNRC6A 3
216450_x_at Tumor rejection antigen 1 TRA1 2 242554_at Two pore segment channel 2 TPCN2 2
229574_at Transformer-2 a TRA2A 2
244871_s_at Ubiquitin-specific protease 32 USP32 2
226176_s_at Ubiquitin-specific protease 42 USP42 2
Genes downregulated in pN+ cases Genes downregulated in ECS+ cases
208848_at Alcohol dehydrogenase 5, chi
polypeptide
ADH5 2 209864_at Frequently rearranged in advanced
T-cell lymphomas 2
FRAT2 2
224655_at Adenylate kinase 3 AK3 2 1555419_a_at N-acylsphingosine amidohydrolase 1 ASAH1 2
210980_s_at N-acylsphingosine amidohydrolase 1 ASAH1 2 213902_at N-acylsphingosine amidohydrolase 1 ASAH1 3
209366_x_at Cytochrome b-5 CYB5 2 212096_s_at Mitochondrial tumor suppressor 1 MTUS1 2
225864_at Family with sequence similarity 84B FAM84B 2 226622_at Mucin 20 MUC20 2
211569_s_at L-3-hydroxyacyl-coenzyme A
dehydrogenase, short chain
HADHSC 2 202174_s_at Pericentriolar material 1 PCM1 2
1555037_a_at Isocitrate dehydrogenase 1 IDH1 3 210145_at Phospholipase A2, group IVA PLA2G4A 2
227297_at Integrin, a9 ITGA9 2 215772_x_at Succinate-coenzyme A ligase,
GDP-forming, b subunit
SUCLG2 2
212956_at KIAA0882 protein KIAA0882 2 200883_at Ubiquinol –cytochrome
c reductase core protein II
UQCRC2 2
222603_at KIAA1815 KIAA1815 2
204249_s_at LIM domain only 2 LMO2 2
202174_s_at Pericentriolar material 1 PCM1 2
212096_s_at Mitochondrial tumor suppressor 1 MTUS1 3
223130_s_at Myosin light chain interacting protein MYLIP 2
209120_at Nuclear receptor subfamily 2,
group F, member 2
NR2F2 2
223315_at Netrin 4 NTN4 2
*Number of times presented in the dChip-, MAS 5.0– , and RMA-based significant gene lists.
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power of identified molecular markers in a large independent
sample set.
Discussion
Lymph Node Metastasis and ECS of HNSCCs
ECS of lymph node metastasis is one of the most impor-
tant negative prognostic factors of HNSCCs [14,15]. How-
ever, the underlying biology determining these aggressive
features is largely unknown. Improvement in patient survival
requires an increased understanding of tumor metastasis so
that aggressive tumors can be detected early in the disease
process and targeted therapeutic interventions can be devel-
oped. We used a global approach to uncover gene expres-
sion signatures associated with these aggressive features.
Because our method covers most of the human transcrip-
tome, the differentially expressed genes consistently seen in
tumors with lymph node metastasis and ECS of the node are
likely to be biologically important. In this study, we identified
Figure 1. Classification of OTSCC lymph node metastasis using global gene expression analysis. Global gene expression profiling on 11 lymph node metastasis –
positive (pN+) and 14 lymph nodemetastasis –negative (pN) SCC samples of the tonguewas carried out usingU133+2.0 array. A signature gene set of 33 geneswas
created based on the integration of three microarray methods (dChip, MAS 5.0, and RMA), as described in the Materials and Methods section. Hierarchical clustering
(A) and MDS (B) were performed based on this signature gene set. The metastasis group (labeled M; n = 11) and the nonmetastasis group (labeled N; n = 14).
Figure 2. Classification of OTSCC node ECS using global gene expression analysis. A second signature gene set was created for the ECS+ group (labeled Y; n = 7)
and the ECS group (labeled N; n = 18). Hierarchical clustering (A) and MDS (B) were performed based on this signature gene set.
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CTTN and MMP9 as consistently overexpressed genes in
tumors with lymph node metastasis that best predict lymph
node metastasis and ECS in our models.
It is important to note that prediction works better when
expressions of several candidate genes were considered at
the same time, suggesting a compounded effect of the genes
on HNSCC progression. Although the precise role of classi-
fication models in predicting patients’ clinical outcomes
needs to be determined in future studies, our results suggest
that these genes may be therapeutic targets for patients with
HNSCC. More importantly, it suggests that targeting a com-
bination of several of these genes may achieve therapeutic
synergy to treat or prevent tumor cell spread and metastasis.
Rationale of Focusing on Tongue Cancer
It has been realized that head and neck cancers are
groups of diverse cancers that develop from many different
anatomic sites and are associated with different risk fac-
tors [29] and genetic characteristics [30]. In this study, we
focused on OTSCC—one of the most common sites for
HNSCC. OTSCC is significantly more aggressive than other
forms of HNSCCs, with a propensity for rapid local invasion
and spread [31]. It is possible that signature gene sets for
tumor metastases of HNSCC originating from different ana-
tomic sites maybe different. More studies will be needed to
address this important question.
Discussion of Validated Candidate Genes
A set of candidate genes, including genes that are known
to be involved in metastasis, such as MMP9 and CTTN, has
been identified and validated in this study. MMP9 is a mem-
ber of a group of secreted zinc metalloproteases, which, in
mammals, degrade the collagen of the extracellular matrix. An
elevated expression of MMP9 has been linked to metastasis
in many different cancer types [32,33]. CTTN has been
shown to be an oncogene residing in the 11q13 region that
is frequently amplified in HNSCC and breast cancer [34,35].
Interestingly, cyclin D1, which also resides in the 11q13 and is
often coupregulated with CTTN [36], does not appear to be
one of the most predictive markers for either pN metastasis
or ECS. Our signature gene set also contains several candi-
date genes that are involved in tumorigenesis, such as BMP2
and EGFR. BMP2 is a member of the transforming growth
factor-b superfamily, which controls proliferation, differentia-
tion, and other functions in many cell types. EGFR is one of
the most frequently amplified and mutated genes in many dif-
ferent type of cancers, including HNSCC [37,38]. Other iden-
tified candidate genes, whose roles in the metastatic process
have not been clearly defined, include GTSE1 and EEF1A1.
GTSE1 is a microtubule-localized protein. Its expression is
cell cycle–regulated and can induce G2/M–phase accumu-
lation when overexpressed [39]. It has been demonstrated
that GTSE1 downregulates the levels and activity of the p53
Table 4. Real-Time qRT-PCR Validation of Selected Candidate Genes.
pN* pN+* Wilcoxon P ECS* ECS+* Wilcoxon P
BMP2 1.19 (0.42–3.45) 4.76 (4.1–9.57) .043 1.57 (0.71–4.59) 7.21 (4.68–10.56) .069
CTTN 1.52 (1.22–3.45) 7.21 (5.58–13.49) <.0001 2.93 (1.37–4.95) 7.21 (6.15–21.73) .004
EEF1A1 0.56 (0.26–1.07) 0.33 (0.21–0.41) .078 0.5 (0.26–0.89) 0.26 (0.16–0.34) .064
ASAH1 1.04 (0.45–1.35) 0.27 (0.14–1.2) .259 0.97 (0.28–1.35) 0.26 (0.12–0.87) .209
MTUS1 0.81 (0.25–1.77) 0.42 (0.09–0.66) .364 0.76 (0.25–1.73) 0.42 (0.09–0.66) .544
GTSE1 1.68 (0.60–2.51) 3.48 (2.48–7.17) .013 2.3 (0.77–3.2) 3.48 (2.22–6.73) .107
MMP9 2.38 (1.48–3.43) 13.0 (5.67–16.30) .001 2.46 (1.52–4.26) 13.93 (9.64–38.43) .001
EGFR 0.71 (0.41–1.72) 3.03 (1.91–5.21) .004 1.11 (0.45–2.69) 3.03 (1.93–7.09) .055
*The median value (25th to 75th percentiles) of the RNA level was computed with the 2DDCt method, as described previously [26], where -actin was used as
reference gene.
Table 5. Classification Power for Selected Candidate Genes Based on Real-Time qRT-PCR.
Prediction Power for pN/pN+ Prediction Power for ECS/ECS+
Wilcoxon P ROC (AUC) Sensitivity Specificity Wilcoxon P ROC (AUC) Sensitivity Specificity
BMP2 .043 74 82 73 .069 74 86 68
CTTN <.0001 94 91 80 .004 88 86 74
EEF1A1 .078 71 55 33 .064 74 57 26
ASAH1 .259 64 27 73 .209 67 29 74
MTUS1 .364 61 64 33 .544 58 57 37
GTSE1 .013 79 73 80 .107 71 71 74
MMP9 .001 88 82 93 .001 95 100 89
EGFR .004 82 73 80 .055 75 71 79
The best model*
Model for pN/pN+ Sensitivity Specificity Overall accuracy
rate (%)
Model for ECS/ECS+ Sensitivity Specificity Overall accuracy
rate (%)
CTTN+MMP9+EGFR 100 100 84.6** CTTN+EEF1A1+MMP9 100 100 84.6**
*The best model is generated based on stepwise logistic model selection.
**The overall accuracy rate is estimated by the leave-one-out cross validation approach.
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tumor-suppressor protein and represses its ability to induce
apoptosis after DNA damage [40]. The EEF1A1 gene codes
for the a subunit of elongation factor-1, which is involved in the
binding of aminoacyl-tRNA to 80S ribosome. The involvement
of this gene with tumorigenesis is not clear.
Rationale of Using Multiple Microarray Analysis Methods
for Identification of Candidate Genes
Several approaches for defining a measure of expression
representing the amount of corresponding mRNA for each
microarray probe set have been proposed. These include the
Affymetrix MAS 5.0 (which is now implemented in GCOS)
[22], theMBEI from Li andWong [23] (implemented in dChip),
and the RMA from Irizarry et al. [24] (implemented in R). Each
approach uses a different data preparatory procedure for
normalization and background correction, and uses its own
model to define the expression index. Consequently, expres-
sion indices will differ when applied to the same probe set
data. These differences reflect varying biologic attributes that
eachmathematical model highlights. Previous studies (David
Elashoff, Myungshin Oh, Nik Brown, Yang Li, David T. Wong,
Steve Horvath, ‘‘Empirical Study of the Influence of Expres-
sion Index on the Standard Statistical Analysis of Oligo-
nucleotide Microarray Data,’’ manuscript in preparation), as
well as our own results here, have found a low level of overlap
between gene lists produced by variousmethods, suggesting
that a combination of methods can be used in the statistical
analysis of oligonucleotide microarray data. This may be a
reflection of the high false-positive rate in microarray-based
studies. A stratagem will be needed to reduce these false-
positives. In addition, it is important to narrow down the
candidate gene list for future validation and eventual imple-
mentation of these biomarkers in a clinical setting.
In this study, to narrow down candidate genes, a final
signature gene set was compiled by selecting genes present
in at least two of three initial candidate gene lists generated
using dChip, MAS 5.0, and RMA. The rationale is that using
a combination of several methods/gene lists will increase
the statistical power to identify true biomarkers, reduce the
chances of false-positives, and improve reproducibility in
downstream validation experiments.
Requirement for Future Validation Studies with Independent
Sample Sets
Our data (ROC analyses) showed the potential of using
these candidate genes as biomarkers for the prediction/clas-
sification of lymph node metastasis and the ECS of OTSCC.
Specific combinations of several markers provide further
enhancement of prediction/classification power. Interestingly,
several markers (CTTN and MMP9) provide superb classifi-
cation power for both pNmetastasis and ECS. This suggests
that the same (or similar) functional/biologic events account
for both pN metastasis and ECS phenotypes, and these
phenotypes are a reflection of continuous progression of
metastasis potential from pNmetastasis to ECS. The specific
thresholds for these markers and the roles used to combine
these markers will most likely be different for the two dis-
tinct phenotypes. Additional studies on a larger sample sets
are needed.
In summary, our results demonstrate the feasibility of
using biomarkers discovered by global expression profiling
analyses as potential biomarkers for the prediction/clas-
sification of OTSCC metastasis and ECS. These results,
together with those from recent studies, will set the stage
for translating this molecular genetic-based finding into clin-
ically valid markers for the prediction and classification of
HNSCC metastasis, pending future validation of these
markers with large independent sample sets.
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